NASDAQ:OPHT - IVERIC bio Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$14.10
▼ -0.76 (-5.11%)
Get New IVERIC bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPHT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPHT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for IVERIC bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $14.10.

This chart shows the closing price for OPHT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in IVERIC bio. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2018Chardan CapitalReiterated RatingHold$4.00Low
6/13/2018Chardan CapitalReiterated RatingHold$4.00Low
3/19/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
9/21/2017Stifel NicolausReiterated RatingHold$4.00Low
12/13/2016GabelliDowngradeBuy ➝ HoldN/A
12/13/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightN/A
12/12/2016The Goldman Sachs GroupUpgradeSell ➝ NeutralN/A
12/12/2016SVB LeerinkDowngradeOutperform ➝ Market PerformN/A
12/12/2016Stifel NicolausDowngradeBuy ➝ HoldN/A
12/12/2016BTIG ResearchDowngradeBuy ➝ NeutralN/A
12/12/2016CowenDowngradeOutperform ➝ Market PerformN/A
12/12/2016CitigroupDowngradeBuy ➝ NeutralN/A
12/12/2016BarclaysDowngradeOverweight ➝ Equal WeightN/A
12/12/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$11.00N/A
12/12/2016SunTrust BanksDowngradeBuy ➝ HoldN/A
12/12/2016Chardan CapitalDowngradeBuy ➝ Neutral$15.00N/A
(Data available from 12/5/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
IVERIC bio logo
IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
Read More

Today's Range

Now: $14.10
Low: $13.88
High: $15.00

50 Day Range

MA: $1.30
Low: $1.13
High: $1.39

52 Week Range

Now: $14.10
Low: $1.02
High: $4.50

Volume

2,984,368 shs

Average Volume

159,109 shs

Market Capitalization

$584.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of IVERIC bio?

The following Wall Street sell-side analysts have issued reports on IVERIC bio in the last twelve months:
View the latest analyst ratings for OPHT.

What is the current price target for IVERIC bio?

0 Wall Street analysts have set twelve-month price targets for IVERIC bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IVERIC bio in the next year.
View the latest price targets for OPHT.

What is the current consensus analyst rating for IVERIC bio?

IVERIC bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OPHT.

How do I contact IVERIC bio's investor relations team?

IVERIC bio's physical mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company's listed phone number is (212) 845-8200 and its investor relations email address is [email protected] The official website for IVERIC bio is www.ophthotech.com.